Public Health Impact After the Introduction of PsA-TT: The First 4 Years

Background. During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010–2011 and its rollout from 2011 to 2013, >150 million eligible people, representing 12 hyperendemic meningitis countries, have been vaccinated. Methods. The new vaccine effectiveness evaluation framework...

Descripción completa

Detalles Bibliográficos
Autores principales: Diomandé, Fabien V. K., Djingarey, Mamoudou H., Daugla, Doumagoum M., Novak, Ryan T., Kristiansen, Paul A., Collard, Jean-Marc, Gamougam, Kadidja, Kandolo, Denis, Mbakuliyemo, Nehemie, Mayer, Leonard, Stuart, James, Clark, Thomas, Tevi-Benissan, Carol, Perea, William A., Preziosi, Marie-Pierre, Marc LaForce, F., Caugant, Dominique, Messonnier, Nancy, Walker, Oladapo, Greenwood, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639484/
https://www.ncbi.nlm.nih.gov/pubmed/26553676
http://dx.doi.org/10.1093/cid/civ499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639484/
https://www.ncbi.nlm.nih.gov/pubmed/26553676
http://dx.doi.org/10.1093/cid/civ499

Ejemplares similares